Idarubicin, cytarabine, etoposide (IA ± E) chemotherapy yielded superior survival, while azacitidine+venetoclax (AZA+VEN) regimens underperformed. The study was registered on the Chinese clinical trial registry (ChiCTR) platform (No. ChiCTR2500096484).

3 days ago

Clinical data • Retrospective data • Journal

TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • CEBPA (CCAAT Enhancer Binding Protein Alpha)

TP53 mutation • FLT3 mutation • NPM1 mutation • KIT mutation • TET2 mutation

Venclexta (venetoclax) • cytarabine • azacitidine • etoposide IV • idarubicin hydrochloride

dexamethasone, ara-C, cisplatin (DHAP) was the most common salvage regimen (47.8%)...BCNU, etoposide, ara-C, melphalan (BEAM) was the most common conditioning regimen 91.9%...t-MN significantly contributes to NRM post-auto-HCT. Age at transplant is the primary risk factor, highlighting the need for vigilant monitoring and risk mitigation strategies.

3 days ago

Journal

TP53 (Tumor protein P53)

cisplatin • cytarabine • etoposide IV • dexamethasone • melphalan

Extensive myeloid sarcoma presenting with esophageal compression and dysphagia as the initial manifestation. (PubMed, Medicine (Baltimore))

Infiltrative mediastinal/retroperitoneal MS may present with esophageal obstruction and mimic lymphoma or carcinoma. High-index suspicion, targeted biopsy with high-power morphology, and a focused immunohistochemical panel are critical for timely diagnosis and treatment initiation.

3 days ago

Journal

KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD20 (Membrane Spanning 4-Domains A1) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD5 (CD5 Molecule) • CD79A (CD79a Molecule) • CD7 (CD7 Molecule) • KRT19 (Keratin 19) • CD2 (CD2 Molecule) • CD99 (CD99 Molecule)

cytarabine • Synribo (omacetaxine mepesuccinate) • aclarubicin

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia (clinicaltrials.gov)

P2, N=70, Suspended, St. Jude Children's Research Hospital | Recruiting --> Suspended

3 days ago

Trial suspension

Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine • etoposide IV • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV

REVEAL-ND NPM1: Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation (clinicaltrials.gov)

P3, N=468, Recruiting, Syndax Pharmaceuticals | Not yet recruiting --> Recruiting

4 days ago

Enrollment open

cytarabine • Revuforj (revumenib)

FIL_V-RBAC: Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL (clinicaltrials.gov)

P2, N=141, Completed, Fondazione Italiana Linfomi - ETS | Active, not recruiting --> Completed

4 days ago

Trial completion

CCND1 (Cyclin D1) • SOX11 (SRY-Box Transcription Factor 11)

Chr t(11;14)

Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • bendamustine

The promise of menin inhibitors: from approval to triplet regimens. (PubMed, Hematology Am Soc Hematol Educ Program)

Next-generation agents (ziftomenib, bleximenib, enzomenib, BMF-219) have displayed similar composite complete remission rates (20-35%) and overall response rates (45-65%) in heavily pretreated KMT2Ar and NPM1m acute myeloid leukemia (AML) with measurable residual disease (MRD) negativity and prolonged overall survival (5-7 months)...Acquired mutations in the menin gene described in 39% of post-revumenib relapses have not been identified following other inhibitors (ziftomenib, bleximenib), prompting new questions about resistance mechanisms. These promising results swiftly led to the launch of multiple trials of menin inhibitors combined with intensive (cytarabine and anthracycline) and nonintensive (venetoclax and hypomethylating) chemotherapy backbones...Ongoing/pending phase 3 trials will clarify whether menin blockade should be incorporated into frontline and maintenance regimens for all patients with KMT2A rearranged or NPM1 mutant disease. In the current era, menin inhibition remains a key pillar of the success of precision medicine for AML therapy.

7 days ago

Review • Journal

NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)

NPM1 mutation • KMT2A rearrangement

Venclexta (venetoclax) • cytarabine • Revuforj (revumenib) • Komzifti (ziftomenib) • icovamenib (BMF-219) • bleximenib (JNJ-6617) • enzomenib (DSP-5336)

Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov)

P1/2, N=53, Active, not recruiting, University of Southern California | Trial primary completion date: Oct 2026 --> Jun 2026

8 days ago

Trial primary completion date

cytarabine • idarubicin hydrochloride • pevonedistat (MLN4924) • Starasid (cytarabine ocfosfate)

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma (clinicaltrials.gov)

P2, N=33, Recruiting, City of Hope Medical Center | Trial completion date: Oct 2027 --> Oct 2029 | Trial primary completion date: Oct 2027 --> Oct 2029

8 days ago

Trial completion date • Trial primary completion date

CD34 (CD34 molecule)

cytarabine • etoposide IV • carmustine • melphalan • Simulect (basiliximab) • Starasid (cytarabine ocfosfate)

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)

P1, N=7, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Oct 2025 --> Oct 2026

8 days ago

Trial completion date

Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Asparlas (calaspargase pegol-mknl)

Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma (clinicaltrials.gov)

P3, N=99, Recruiting, The Affiliated People's Hospital of Ningbo University | Trial completion date: Dec 2026 --> Aug 2026 | Trial primary completion date: Dec 2026 --> Aug 2026

8 days ago

Trial completion date • Trial primary completion date

cisplatin • carboplatin • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV

10d

GANCE: Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML (clinicaltrials.gov)

P2, N=25, Not yet recruiting, First Affiliated Hospital of Zhejiang University

10 days ago

New P2 trial

BCL2 (B-cell CLL/lymphoma 2)

Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine